@article{6abdf7c6f87143a3a9a057a3b29f748d,
title = "Workshop report from the national institutes of health taskforce on the research needs of eosinophil-associated diseases (TREAD)",
abstract = "Background: Eosinophils are blood cells that are often found in high numbers in the tissues of allergic conditions and helminthic parasite infections. The pathophysiologic roles that eosinophils may serve in other human {"}eosinophil-associated{"} diseases remain obscure. Objective: National Institutes of Health (NIH) Institutes and the Office of Disease Prevention assembled an international taskforce of clinical and basic scientists with the charge to propose and prioritize unmet research needs in eosinophil-associated diseases. Methods: The taskforce used an organ system approach to identify the different and common themes of eosinophil cell involvement in these diseases. In early 2012, a draft document was circulated for review. The document was amended and the prioritizations were set at a NIH-organized workshop in June 2012. Results: The taskforce identified significant research needs. These needs cross disease entities but some are disease specific. There are substantial shortcomings to the various preclinical animal models, as well as significant gaps in our epidemiologic, pathophysiologic, diagnostic, prognostic, and therapeutic knowledge. The taskforce recognized that recent efforts by patient advocacy groups have played instrumental roles in improving the identification and characterization of these disorders. However, communications among the eosinophil-interested communities, for example, governmental funding and regulatory agencies, and industry and clinician scientists need to be more comprehensive. Conclusions: Significant efforts are required to address our knowledge gaps to improve the outcomes of eosinophil-associated diseases. NIH Institutes, other federal agencies, lay organizations, and the pharmaceutical industry should consider the taskforce's recommendations in their future research activities.",
keywords = "Churg-Strauss syndrome, Eosinophil, apoptosis, coagulopathy, discovery, fusion oncoproteins, hypereosinophilic syndromes, research, therapeutics",
author = "Bochner, {Bruce S.} and Wendy Book and Busse, {William W.} and Joseph Butterfield and Furuta, {Glenn T.} and Gleich, {Gerald J.} and Klion, {Amy D.} and Lee, {James J.} and Leiferman, {Kristin M.} and Michael Minnicozzi and Redwan Moqbel and Rothenberg, {Marc E.} and Schwartz, {Lawrence B.} and Simon, {Hans Uwe} and Wechsler, {Michael E.} and Weller, {Peter F.}",
note = "Funding Information: Disclosure of potential conflict of interest: B. S. Bochner has received grants from the National Institute of Allergy and Infectious Diseases (NIAID) and the National Heart, Lung, and Blood Institute; has consultant arrangements with Sanofi-Aventis, Genentech, Merck, Roche, GlaxoSmithKline, TEVA, GlycoFi, and Medicis; is on scientific advisory boards for Merck and Allakos; is a co-inventor on existing and pending Siglec-8 related patents; may be entitled to a share of royalties on the potential sales of Siglec-8-related products; receives royalties from UpToDate and Elsevier; is a co-founder of and has purchased stock in Allakos, Inc; and holds stock options for Glycomimetics, Inc. W. M. Book has received public education grants on behalf of the American Partnership for Eosinophilic Disorders from Abbott Nutrition and Nutricia. W. W. Busse has received grants from the National Institutes of Health (NIH)/NIAID; has served on an advisory board for Merck; has consulted for Amgen, AstraZeneca, Novartis, GlaxoSmithKline, MedImmune, and Genentech; and has received royalties from Elsevier. J. Butterfield has received royalty payments for licensing of technology from the Mayo Clinic. G. J. Gleich is on the board of the American Partnership for Eosinophilic Disorders; has consulted for GlaxoSmithKline; has received grants from TRIA Bioscience Corp and ImmViz; has patent agreements with ImmViz; has received royalties from Teva; and has stock or stock options in Immune Design Corp. J. J. Lee has received grants from the National Institutes of Health and royalties from the Mayo Foundation for Medical Education and Research. K. M. Leiferman is co-director for the Immunodermatology Laboratory, Department of Dermatology; has received payment for lectures from the American Academy of Allergy, Asthma, & Immunology/American College of Allergy, Asthma, & Immunology Joint Board Review Course 2012; has a patent with ImmViz; and is the spouse of co-author Gerald Gleich. R. Moqbel has consulted for GlaxoSmithKline Canada; has received grants from CIHR (Canada), MHRC, and MICH; and holds a patent on diagnosing respiratory diseases with urine metabolites identified by nuclear magnetic resonance. M. E. Rothenberg is Chief Scientific Officer of Immune Pharmaceuticals; has consultant arrangements with TEVA Pharmaceuticals; has received grants from the NIH; is the inventor of patents owned by Cincinnati Children's Hospital Medical Center; and has stock/stock options in IMMUNE Pharmaceuticals. L. Schwartz has received grants from GlaxoSmithKline, Genentech, Carolus, and NeilMed; has received support for travel from the NIH; is president of the Clinical Immunology Society; is a board member of the Asthma & Allergy Foundation of America; has consultant arrangements with Genentech, Marshall Edwards Inc, and Sanofi-Aventis; and receives royalties from ThermoFisher, Hycult & BioLegend, and Millpore. H.-U. Simon has consultant arrangements with Pfizer. M. Wechsler has received grants from the NIH; has consultant arrangements with GlaxoSmithKline, Cephalon, Novartis, Sepracor/Sunovion, Schering Plough, NKT Therapeutics, Asthmatx/BSCI, Genzyme, MapPharma, Genentech, and Boehringer Ingelheim; and has received honoraria from Merck. P. Weller has consultant arrangements with GlaxoSmithKline. The rest of the authors declare that they have no relevant conflicts of interest. Funding Information: Supported by the National Institute of Allergy and Infectious Diseases and the Office of Disease Prevention . ",
year = "2012",
month = sep,
doi = "10.1016/j.jaci.2012.07.024",
language = "English (US)",
volume = "130",
pages = "587--596",
journal = "Journal of Allergy and Clinical Immunology",
issn = "0091-6749",
publisher = "Mosby Inc.",
number = "3",
}